Scholars Central

Conference abstractPublished 29 Apr 2019

Midterm experience of adult extracorporeal membrane oxygenation: Cardiorespiratory failure

Authors: Kewal Krishan

Max Super Specialty Hospital, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Extracorporeal Membrane Oxygenation (ECMO) is a rescue therapy for critically ill patients with reversible cardiorespiratory pathology and those who have probability of death around 80% despite maximal conventional treatment. The positive results of the recent trials have stimulated our interest to use ECMO for life threating conditions due to cardiorespiratory failure. Here we describe our experience at a tertiary care center in India. We established an adult ECMO program for cardiorespiratory support in April 2013. In the last five years, we supported 60 patients on ECMO and it was only considered once the conventional therapy deemed failing. A retrospective analysis of our patient data was performed to collect information regarding patient demographics, indication for ECMO, type of ECMO and outcomes. A total of 60 patients received ECMO during 2013 to 2018. The mean age was 36.4 years (range 18-57 years), 42 male and 18 female. Out of 60, 10 were Veno-Arterial (VA) and 50 were Veno-Venous (VV) ECMO. In VA ECMO the first patient had intractable arrhythmias and second had acute viral myocarditis leading to refractory cardiogenic shock. Out of 50 patients of VV ECMO, 38 viral pneumonia, 7 bacterial pneumonia and 3 with fulminant fungal infection leading to ARDS 2 had Wegener’s granulomatosis. ECMO was instituted by peripheral cannulation in all patients. Average support time was 13 days (range 7 to 52 days). Thirty six patients (60%) were successfully separated from ECMO and 35 survived to hospital discharge. Four patients had major complications including pump failure and bleeding. One underwent lobectomy for multiple bronchopleural fistulae in right lung. ECMO is salvage therapy in patients with life threating refractory circulatory shock or severe ARDS. This therapy has the potential to save lives if applied in time and in appropriate clinical settings.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Clinical and Experimental Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical and Experimental Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “Kewal Krishan”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels